⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16389544 | 0.81 | — | — | |
| SCHEMBL3057644 | 0.79 | — | — | |
| SCHEMBL31281659 | 0.79 | — | — | |
| SCHEMBL28102759 | 0.76 | MAPK1 (0.35) | — | |
| SCHEMBL21555682 | 0.75 | KMT2A (0.44) | — | |
| SCHEMBL2418235 | 0.74 | HSD17B10 (0.43) | — | |
| SCHEMBL161241 | 0.73 | — | — | |
| SCHEMBL28257547 | 0.73 | L3MBTL1 (0.45) | — | |
| SCHEMBL483937 | 0.73 | — | — | |
| SCHEMBL38507 | 0.73 | L3MBTL1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743457-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| EP-4608988-A1 | CLOSED-LOOP OPTIMIZATION OF GENERAL REACTION CONDITIONS FOR HETEROARYL SUZUKI-MIYAURA COUPLING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025015045-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024240894-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024091573-A1 | CLOSED-LOOP OPTIMIZATION OF GENERAL REACTION CONDITIONS FOR HETEROARYL SUZUKI-MIYAURA COUPLING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3157938-B1 | HETERO FUNCTIONAL BINDING SYSTEMS | ANTEO TECH PTY LTD (AU) | 2022-03-16 | — | — | EP | disclosed |
| US-10768176-B2 | Hetero functional binding systems | ANTEO TECHNOLOGIES PTY LTD (AU) | 2020-09-08 | — | — | US | disclosed |
| US-20170115285-A1 | HETERO FUNCTIONAL BINDING SYSTEMS | ANTEO TECHNOLOGIES PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
| EP-3157938-A1 | HETERO FUNCTIONAL BINDING SYSTEMS | Anteo Technologies Pty Ltd. (AU) | 2017-04-26 | — | — | EP | disclosed |
| US-8530663-B2 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | THERAVANCE, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2550252-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | Theravance, Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| CN-102256963-A | Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INT | 2011-11-23 | — | — | CN | disclosed |
| WO-2011119461-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119461-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230495-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-22 | — | — | US | disclosed |
| CN-1368884-A | Method for modulating FXR receptor activity | ALLERGAN SALES INC (US) | 2002-09-11 | — | — | CN | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |